Agilent Technologies (NYSE:A) Stock Price Target Raised at Barclays

Agilent Technologies (NYSE:A) had its price objective raised by Barclays from $175.00 to $195.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage currently has an “overweight” rating on the medical research company’s stock. Barclays‘s price objective suggests a potential upside of 15.01% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. Sanford C. Bernstein increased their target price on Agilent Technologies from $155.00 to $180.00 and gave the company an “outperform” rating in a report on Thursday, August 27th. Jefferies Financial Group started coverage on shares of Agilent Technologies in a research report on Thursday, July 9th. They issued a “hold” rating and a $135.00 price objective on the stock. Royal Bank Of Canada increased their target price on shares of Agilent Technologies from $155.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, August 27th. Piper Sandler began coverage on Agilent Technologies in a report on Thursday, June 11th. They set a “neutral” rating and a $150.00 target price for the company. Finally, Morgan Stanley boosted their price target on shares of Agilent Technologies from $160.00 to $175.00 and gave the company an “overweight” rating in a research report on Wednesday, August 12th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have given a Hold rating to the company. According to MarketBeat, Agilent Technologies presently has an average rating of “Moderate Buy” and a consensus price target of $171.44.

Agilent Technologies Price Performance

Shares of NYSE:A opened at $169.54 on Wednesday. The firm has a market capitalization of $47.80 billion, a PE ratio of 33.56, a P/E/G ratio of 2.61 and a beta of 1.21. The company has a quick ratio of 1.56, a current ratio of 2.05 and a debt-to-equity ratio of 0.50. The company has a 50-day moving average price of $154.04 and a two-hundred day moving average price of $134.38. Agilent Technologies has a twelve month low of $108.35 and a twelve month high of $177.05.

Agilent Technologies (NYSE:A) last posted its earnings results on Wednesday, August 26th. The medical research company reported $1.62 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.13. The business had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.84 billion. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The company’s quarterly revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.37 EPS. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. Equities analysts forecast that Agilent Technologies will post 6.2 EPS for the current year.

Insider Buying and Selling at Agilent Technologies

In related news, Director Mikael Dolsten sold 634 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were sold at an average price of $151.38, for a total transaction of $95,974.92. Following the completion of the transaction, the director directly owned 4,924 shares of the company’s stock, valued at approximately $745,395.12. This trade represents a 11.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Institutional Trading of Agilent Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Eastern Bank grew its stake in Agilent Technologies by 12.9% in the third quarter. Eastern Bank now owns 2,819 shares of the medical research company’s stock worth $486,000 after purchasing an additional 323 shares in the last quarter. QRG Capital Management Inc. raised its position in shares of Agilent Technologies by 7.6% in the 2nd quarter. QRG Capital Management Inc. now owns 49,576 shares of the medical research company’s stock worth $6,585,000 after acquiring an additional 3,503 shares in the last quarter. Envestnet Asset Management Inc. boosted its position in Agilent Technologies by 36.2% during the second quarter. Envestnet Asset Management Inc. now owns 943,900 shares of the medical research company’s stock valued at $125,378,000 after purchasing an additional 250,989 shares in the last quarter. State Street Corp grew its stake in Agilent Technologies by 0.7% in the second quarter. State Street Corp now owns 12,854,230 shares of the medical research company’s stock valued at $1,710,658,000 after purchasing an additional 89,598 shares during the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Agilent Technologies by 9.7% in the second quarter. The Manufacturers Life Insurance Company now owns 163,805 shares of the medical research company’s stock worth $21,758,000 after purchasing an additional 14,435 shares in the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc is an analytical measurement and laboratory technology company serving the life sciences, diagnostics, pharmaceutical, chemical, environmental, food, energy and academic research markets. Its solutions help laboratories analyze the composition, quality and performance of materials, biological samples and other substances.

The company’s products and services include liquid and gas chromatography systems, mass spectrometry instruments, spectroscopy equipment, laboratory automation tools, software, consumables and supplies.